tbuckley/cabot-search huggingface dataset:
P43 Hyperpolarised xenon-129 MRI of lungs in healthy volunteers: a safety &amp; feasibility study
Authors: S Safavi, J Thorpe, B Haywood, M Barlow, IP Hall
Journal: Thorax (2016)

<h3>Introduction</h3> Conventional proton MRI, although non-invasive and non-ionising, is of little value in imaging the lungs due to poor signal intensity. Hyperpolarised xenon-129 MRI (129Xe-MRI) is a novel technique developed to enhance the applicability of MRI in lung imaging. It has the potential to provide not only anatomical data but also regional lung function data, particularly as xenon is highly lipophilic, and can be use as a gas exchange probe. <h3>Aim</h3> We aimed to assess the feasibility and tolerability of 129Xe-MRI in healthy adult volunteers. <h3>Method</h3> This was a single centre prospective observational study. Ethical approval had been obtained. The volunteers had provided written informed consent. A GE 2000 polariser was used for production of hyperpolarised 129Xe, with a 1.5T GE MRI scanner for imaging. The volunteers underwent a conventional MRI thorax, followed by 129Xe-MRI of lungs. The inhaled volume of hyperpolarised 129Xe ranged 0.6–1.0L. There was 30 minutes of observation with recording of vital signs, i.e., oxygen saturations (O2 sats), heart rate (HR), and blood pressure (BP) at 5, 10, 15, and 30 minutes post-inhalation of xenon, after each scan. Each visit comprised of a maximum of four scans. <h3>Results</h3> Nine volunteers (male: female 8:1, aged 20–34) underwent 28 scan visits, comprising of 102 scans. 129Xe-MRI was well-tolerated, with no serious adverse events. The polarisation achieved ranged 4.10–10.57%. To assess the impact of inhaling xenon on vital signs as a safety measure, the recorded vital signs were analysed using student’s t-test. There was no significant change in O2 sats or BP. The most notable change was noted in HR, which was persistently reduced following inhaling xenon (p &lt; 0.001). These changes were not deemed clinically significant. We achieved good image quality (Figure 1). Spectroscopy distinguished lung tissue-dissolved xenon from blood-dissolved. Dissolved phase imaging (DPI) was obtained. The technique was reproducible. <h3>Discussion</h3> The data demonstrates satisfactory feasibility and tolerability of 129Xe-MRI. DPI can image regional gas exchange. 129Xe-MRI may be used to develop biomarkers of disease progression, and assess drug efficacy, to personalise medicine, reduce healthcare costs, and lower cost and duration of drug development.
P2.03a-014 A Dose-Finding and Phase 2 Study of Ruxolitinib plus Pemetrexed/Cisplatin for Nonsquamous Non–Small Cell Lung Cancer (NSCLC)
Authors: Giuseppe Giaccone, Rachel Sanborn, Saiama Waqar, Alex Martinez, Santiago Ponce, Huiling Zhen, Gerard Kennealey, Susan Erickson-Viitanen, Eric Schaefer
Journal: Journal of Thoracic Oncology (2017)
Impaired H3K36 methylation defines a subset of head and neck squamous cell carcinomas
Authors: Simon Papillon-Cavanagh, Chao Lu, Tenzin Gayden, Leonie G Mikael, Denise Bechet, Christina Karamboulas, Laurie Ailles, Jason Karamchandani, Dylan M Marchione, Benjamin A Garcia, Ilan Weinreb, David Goldstein, Peter W Lewis, Octavia Maria Dancu, Sandeep Dhaliwal, William Stecho, Christopher J Howlett, Joe S Mymryk, John W Barrett, Anthony C Nichols, C David Allis, Jacek Majewski, Nada Jabado
Journal: Nature Genetics (2017)
P3.02c-099 A Retrospective Study of the Efficacy and Safety of Nivolumab in Our Clinical Practice: A Single Institutional Experience
Authors: Tadashi Sakaguchi, Osamu Hataji, Yuta Suzuki, Haruko Saiki, Kentaro Ito, Yoichi Nishii, Kosuke Hayashi, Fumiaki Watanabe, Tetsu Kobayashi, Esteban Gabazza, Osamu Taguchi
Journal: Journal of Thoracic Oncology (2017)
Biochemical and Functional Analysis of Germline KRAS Mutations That Cause Disorders of the Noonan Syndrome Spectrum.
Authors: Suzanne Schubbert, Oddmund Sovik, Gideon Bollag, Hoa Nguyen, Sara L. Rowe, Christian Kratz, Martin M. Zenker, Charlotte Marie Niemeyer, Anders Molven, Kevin Shannon
Journal: Blood (2006)
S22 Severity of sleep disordered breathing independently predicts metabolic dysfunction in a large population of severely obese subjects: the esada study
Authors: BD Kent, N Gildeh, P Drakatos, L Grote, J Hedner, WT McNicholas
Journal: Thorax (2016)

<h3>Introduction</h3> Obstructive sleep apnoea (OSA) has an established independent association with insulin resistance and type 2 diabetes mellitus (T2DM). However, there are few data examining this relationship in severely obese populations, wherein any detrimental effect of OSA on metabolic health may conceivably be drowned out by the impact of morbid obesity. We assessed the relationship of OSA severity and nocturnal hypoxaemia with metabolic health in a cohort of severely obese patients attending sleep units across Europe. <h3>Methods</h3> We performed a cross-sectional analysis of 1,434 participants in the European Sleep Apnea Cohort (ESADA) study with a body mass index (BMI) ≥35 kg/m<sup>2</sup>, using multivariate regression analysis to assess T2DM prevalence according to OSA severity indices. Patients with diabetes were identified by history and medication prescription, and by screening for undiagnosed diabetes with glycosylated haemoglobin (HbA1c) measurement. The relationship of OSA severity with glycaemic control was assessed in diabetic subjects. Multivariate linear regression and multivariate analysis of co-variance were used to examine the relationship of HbA1c levels with OSA severity in both diabetic and non-diabetic patients. <h3>Results</h3> In a cohort of predominantly male (63.5%) and severely obese (mean BMI 40.3 kg/m<sup>2</sup>) individuals, 32.2% had T2DM. Although the likelihood of T2DM was significantly greater in the highest AHI quartile than the lowest (unadjusted OR 1.78; 95% CI: 1.29–2.47), this relationship lost significance following adjustment for anthropometric, demographic, and clinical factors (adjusted OR 1.21; 95% CI: 0.83–1.76; p = 0.33). However, severity of nocturnal hypoxaemia remained a predictor of T2DM prevalence despite adjustment for confounding factors (adjusted OR for most severe mean nocturnal SpO<sub>2 </sub>quartile 2.23; 95% CI: 1.50–2.20; p &lt; 0.001), as well as predicting the likelihood of poor diabetic control (adjusted OR 1.87; 95% CI: 1.06–3.30; p = 0.03). In further analyses, HbA1c levels were independently predicted by OSA severity indices and nocturnal hypoxaemia in both non-diabetic and diabetic subjects, while adjusted mean HbA1c levels were significantly higher in patients with more severe sleep disordered breathing. <h3>Conclusion</h3> Metabolic health in severely obese sleep patients appears to be significantly worse in those subjects with more severe sleep disordered breathing, with a particularly strong relationship with the degree of nocturnal hypoxaemia.
The Combined Use of Hydroxyurea and Anagrelide Allows Better Hematologic Control in Patients with Chronic Myeloproliferative Disorders and Thrombocytosis. A Report on 13 Patients with Poor Tolerance to Hydroxyurea Monotherapy.
Authors: Moira Micheletti, Mariella D’Adda, Monica Drera, Samantha Ferrari, Giuseppe Rossi
Journal: Blood (2006)
hucMSC Exosome-Derived GPX1 Is Required for the Recovery of Hepatic Oxidant Injury
Authors: Yongmin Yan, Wenqian Jiang, Youwen Tan, Shengqiang Zou, Hongguang Zhang, Fei Mao, Aihua Gong, Hui Qian, Wenrong Xu
Journal: Molecular Therapy (2017)

Exosomes are small biological membrane vesicles secreted by various cells, including mesenchymal stem cells (MSCs). We previously reported that MSC-derived exosomes (MSC-Ex) can elicit hepatoprotective effects against toxicant-induced injury. However, the success of MSC-Ex-based therapy for treatment of liver diseases and the underlying mechanisms have not been well characterized. We used human umbilical cord MSC-derived exosome (hucMSC-Ex) administrated by tail vein or oral gavage at different doses and, in engrafted liver mouse models, noted antioxidant and anti-apoptotic effects and rescue from liver failure. A single systemic administration of hucMSC-Ex (16 mg/kg) effectively rescued the recipient mice from carbon tetrachloride (CCl4)-induced liver failure. Moreover, hucMSC-Ex-derived glutathione peroxidase1 (GPX1), which detoxifies CCl4 and H2O2, reduced oxidative stress and apoptosis. Knockdown of GPX1 in hucMSCs abrogated antioxidant and anti-apoptotic abilities of hucMSC-Ex and diminished the hepatoprotective effects of hucMSC-Ex in vitro and in vivo. Thus, hucMSC-Ex promote the recovery of hepatic oxidant injury through the delivery of GPX1.
OA12.06 A Retrospective Analysis of Patients with Small Lung Adenocarcinoma (≤2cm) by New World Health Organization Classification
Authors: Keita Nakao, Jun-Ichi Nitadori, Shigeki Morita, Hideki Kuwano, Kazuhiro Nagayama, Masaki Anraku, Aya Shinozaki-Ushiku, Masaaki Sato, Masashi Fukayama, Jun Nakajima
Journal: Journal of Thoracic Oncology (2017)
Expression of CD25+ Cell Subsets after Induction Chemotherapy in Adult Patients with Acute Myeloid Leukemia.
Authors: Woo-Sung Min, Hee-Je Kim, Young Choi, Sung-Yong Kim, Ki-Sung Eom, Yoo-Jin Kim, Seok Lee, Chang-Ki Min, Jong-Wook Lee, Chun-Choo Kim
Journal: Blood (2005)
P3.02c-068 Immunotherapy against Non-Small Cell Lung Cancer (NSCLC): Looking for Predictive Factors to Avoid an Untargeted Shooting
Authors: Luca Paglialunga, Guido Bellezza, Alessio Gili, Biagio Ricciuti, Vincenzo Minotti, Rita Chiari, Giulio Metro, Vienna Ludovini, Roberta Matocci, Daniela Colabrese, Sara Baglivo, Lucio Crinò, Chiara Bennati
Journal: Journal of Thoracic Oncology (2017)
High Circulating Levels of Sclerostin Correlate with Bone Mineral Density In Patients with Thalassemia and Osteoporosis: The Role of the Wnt Signaling In the Pathogenesis of Bone Loss In Thalassemia
Authors: Ersi Voskaridou, Dimitrios Christoulas, Athanasios Papatheodorou, Cornelia Bratengeier, Eleni Plata, Despoina Kaliontzi, Wolfgang Woloszczuk, Evangelos Terpos
Journal: Blood (2010)
S72 Immunomodulatory effects of carbon particulates on macrophage handling of streptococcal infections
Authors: HL Shaw, JC Wallington, M Christodoulides, DI Phillips, TMA Wilkinson, KJ Staples
Journal: Thorax (2016)

<h3>Background and objective</h3> Airway macrophages are key to a successful immune response to pulmonary infections. Smoke exposure has been previously shown to result in particulate loading of alveolar macrophages and subsequent impaired macrophage responses to infection with <i>Streptococcus pneumoniae</i>.<sup>1</sup> Rheumatic heart disease (RHD) is an autoimmune disorder that follows an airway infection with <i>Streptococcus pyogenes</i> in some individuals. Little is understood about the aetiological factors predisposing the development of RHD but smoke exposure from combustion of solid fuels has recently been epidemiologically linked to RHD. In the context of this epidemiological observation, we hypothesised that smoke exposure would affect macrophage handling of <i>Streptococcus pyogenes </i>in a similar manner to that observed in studies with <i>Streptococcus pneumoniae.</i> <h3>Methods</h3> Human positively-isolated CD14+ monocyte-derived macrophages (MDM), an established model for alveolar macrophages, were incubated with an optimised dose of carbon particulates. Phagocytosis of <i>Streptococcus pneumoniae </i>and<i> pyogenes </i>was assessed by bacterial culture of macrophages lysates. Autologous CD3+ T cells were co-cultured with infected MDM for 24 h. Expression of cell surface markers, T cell activation and uptake of FITC beads were assessed by flow cytometry. <h3>Results</h3> Phagocytosis of <i>Streptococcus pneumoniae </i>and<i> pyogenes </i>by carbon loaded MDM was impaired compared to non-carbon loaded MDM (18.8% reduction, p = 0.01). Phagocytosis of FITC beads was also shown to be reduced by the carbon loaded MDM (10% reduction, p = 0.03). Carbon loading decreased MDM surface expression of the phagocytic receptor CD36 (p &lt; 0.01) and decreased the surface expression of antigen presentation molecules HLA-ABC and HLA-DR (p = 0.04 and 0.03 respectively). Addition of <i>S. pyogenes</i> increased expression of HLA-DR only on the cell surface of carbon loaded MDM (p = 0.02). Preliminary results suggest that autologous T cells express IFNγ in response to coculture with infected MDM and that this response is enhanced in carbon loaded MDM. <h3>Conclusion</h3> We conclude that carbon exerts immunomodulatory effects on MDM phagocytosis of <i>Streptococcus pyogenes</i> and subsequent antigen presentation. Further investigation of this subject in the context of both chronic lung infection and RHD is therefore warranted. <h3>Reference</h3> Rylance J, <i>et al</i>. Household air pollution causes dose-dependent inflammation and altered phagocytosis in human macrophages. <i>AJRCMB</i> 2015;<b>52</b>(5):584–93.
Leptin in the interplay of inflammation, metabolism and immune system disorders
Authors: Vanessa Abella, Morena Scotece, Javier Conde, Jesús Pino, Miguel Angel Gonzalez-Gay, Juan J. Gómez-Reino, Antonio Mera, Francisca Lago, Rodolfo Gómez, Oreste Gualillo
Journal: Nature Reviews Rheumatology (2017)
P3.01-063 XIAP Inhibits Mature Smac Induced Apoptosis by Degrading It through Ubiquitination in NSCLC
Authors: Sida Qin, Chengcheng Yang, Boxiang Zhang, Xiang Li, Xin Sun, Gang Li, Jing Zhang, Guodong Xiao, Xiao Gao, Guanghong Huang, Peili Wang, Hong Ren
Journal: Journal of Thoracic Oncology (2017)
P1.05-001 Creation and Early Validation of Prognostic miRNA Signatures for Squamous Cell Lung Carcinoma by the SPECS Lung Consortium
Authors: David Harpole, Raphael Bueno, William Richards, David Beer, Karla Ballman, Ming Tsao, Frances Shepard, Daniel Merrick, Adriaan Van Bokhoven, Wilbur Franklin, Ramaswamy Govindan, Mark Watson, David R. Gandara, Guoan Chen, Zhengming Chen, Lucian Chirieac, Herman Chui, Carlo Genova, Mary-Beth Joshi, Ashley Kowalewski, Mark Onaitis, Christopher Rivard, Thomas Sporn, Fred R. Hirsch
Journal: Journal of Thoracic Oncology (2017)
Randomized Phase II Study of Two Schedules of Flavopiridol (Alvocidib, F) Given as Timed Sequential Therapy (TST) Wtih Ara-C and Mitoxantrone (FLAM) for Adults with Newly Diagnosed, Poor-Risk Acute Myelogenous Leukemia (AML)
Authors: Judith E. Karp, John M. Pagel, B. Douglas Smith, Jacqueline M Greer, D. Michelle Drye, Kelly M. Smith, Kathleen Dorcy, John J Wright, L. Austin Doyle, Elizabeth Garrett-Mayer, Elihu H. Estey
Journal: Blood (2010)
P1.08-010 Octogenarians Perform Equally to Younger Patients in Lung Cancer Surgery
Authors: Florian Kocher, Caecilia Ng, Herbert Maier, Magdalena Sacher, Gregor Laimer, Michael Fiegl, Paolo Lucciarini, Thomas Schmid, Florian Augustin
Journal: Journal of Thoracic Oncology (2017)
Activation of CECR1 in M2-like TAMs promotes paracrine stimulation-mediated glial tumor progression
Authors: Changbin Zhu, Dana Mustafa, Ping-pin Zheng, Marcel van der Weiden, Andrea Sacchetti, Maarten Brandt, Ihsan Chrifi, Dennie Tempel, Pieter J. M. Leenen, Dirk Jan Duncker, Caroline Cheng, Johan M. Kros
Journal: Neuro-Oncology (2016)

The majority of glioma-associated microglia/macrophages have been identified as M2-type macrophages with immune suppressive and tumor supportive action. Recently, the extracellular adenosine deaminase protein Cat Eye Syndrome Critical Region Protein 1 (CECR1) was shown to regulate macrophage maturation. In this study, we investigate the role of CECR1 in the regulation of the glioma-associated macrophage response.Expression of CECR1 was assessed in human glioma samples. CECR1-mediated macrophage response was studied in vitro, using donor derived CD14+ monocytes and the THP-1 monocytic cell line. The response of the human glioma cell line U87 to conditioned medium of macrophages preconditioned with recombinant human CECR1 or CECR1 silencing was also assessed.CECR1 was strongly expressed in high-grade gliomas (P < .001) and correlated positively with the M2 phenotype markers in tumor-associated microglia/macrophages (TAMs) (overall, P < .05). In vitro studies confirmed the presence of a significantly higher level of CECR1 expression in M2-like macrophages exposed to U87 conditioned medium (P < .001). CECR1 knockdown or stimulation of macrophages affected differentiation toward the M2-like phenotype. Stimulation of U87 cells with conditioned medium of CECR1 knockdown or stimulated macrophages affected tumor cell proliferation and migration, coinciding with altered intracellular signaling of mitogen-activated protein kinase (MAPK). In glioma tissue samples, CECR1 expression correlated with Ki67 and MAPK signaling protein.CECR1 is a potent regulator of TAM polarization and is consistently highly expressed by M2-type TAMs, particularly in high-grade glioma. Paracrine effects induced by CECR1 in M2-like TAMs activate MAPK signaling and stimulate the proliferation and migration of glioma cells.
The Src-Abl Kinase Inhibitor Dasatinib (BMS-354825) Shows Anti-Proliferative and Anti-Apoptotic Effects in Chronic Lymphocytic Leukemia (CLL) Cells In Vitro.
Authors: Aditya Veldurthy, Michaela Patz, Christian P. Pallasch, Clemens M. Wendtner, Michael Hallek, Gunter F. Krause
Journal: Blood (2007)
Identification of CCR2 and CD180 as Robust Pharmacodynamic Tumor and Blood Biomarkers for Clinical Use with BRD4/BET Inhibitors
Authors: Tammie C. Yeh, Greg O'Connor, Philip Petteruti, Austin Dulak, Maureen Hattersley, J. Carl Barrett, Huawei Chen
Journal: Clinical Cancer Research (2017)

Abstract Purpose: AZD5153 is a novel BRD4/BET inhibitor with a distinctive bivalent bromodomain binding mode. To support its clinical development, we identified pharmacodynamic (PD) biomarkers for use in clinical trials to establish target engagement. Experimental Design: CCR2 and CD180 mRNAs, initially identified from whole transcriptome profiling, were further evaluated by quantitative PCR in hematologic cell lines, xenografts, and whole blood from rat, healthy volunteers, and patients with cancer. MYC and HEXIM1 mRNAs were also evaluated. Results: RNA-sequencing data showed consistent decreases in CCR2/CD180 expression across multiple hematologic cell lines upon AZD5153 treatment. Evaluation of dose dependence in MV4,11 cells confirmed activity at clinically relevant concentrations. In vivo downregulation of CCR2/CD180 mRNAs (&amp;gt;80%) was demonstrated in MV4,11 and KMS-11 xenograft tumors at efficacious AZD5153 doses. Consistent with in vitro rat blood data, an in vivo rat study confirmed greater inhibition of CCR2/CD180 mRNA in whole blood versus MYC at an efficacious dose. Finally, in vitro treatment of whole blood from healthy volunteers and patients with cancer demonstrated, in contrast to MYC, almost complete downregulation of CCR2/CD180 at predicted clinically achievable concentrations. Conclusions: Our data strongly support the use of CCR2 and CD180 mRNAs as whole blood PD biomarkers for BRD4 inhibitors, especially in situations where paired tumor biopsies are unavailable. In addition, they can be used as tumor-based PD biomarkers for hematologic tumors. MYC mRNA is useful as a hematologic tumor-based biomarker but suboptimal as a whole blood biomarker. Utility of HEXIM1 mRNA may be limited to higher concentrations. Clin Cancer Res; 23(4); 1025–35. ©2017 AACR.
Melanized fungal infections in kidney transplant recipients: contributions to optimize clinical management
Authors: D.W. Santos, L.F. Camargo, S.S. Gonçalves, M.M. Ogawa, J. Tomimori, M.M. Enokihara, J.O. Medina-Pestana, A.L. Colombo
Journal: Clinical Microbiology and Infection (2017)
Dosimetry, toxicity, and response in a phase IIa trial of no-carrier added iobenguane I-131 (nca-MIBG): A New Approach to Neuroblastoma Therapy (NANT) study.
Authors: K. K. Matthay, B. D. Weiss, J. Villablanca, J. M. Maris, G. A. Yanik, S. G. Groshen, H. Jackson, R. Hawkins, F. Goodarzian, A. Panigrahy, S. G. DuBois, J. Stubbs, A. Towbin, J. A. Barrett, N. D. LaFrance, J. W. Babich
Journal: Journal of Clinical Oncology (2011)

9512 Background: 131I-MIBG is specifically taken up in neuroblastoma, with a response rate >30% in relapsed disease. The presence of non-radioactive “carrier” MIBG molecules increases risk of cardiovascular side effects and can inhibit tumor uptake of 131I-MIBG, reducing tumor radiation. Our primary aim was to establish the maximum tolerated dose (MTD) of no-carrier-added MIBG with autologous hematopoietic stem cell (AHSC) support. Methods: Eligible patients were age 1-30 years with resistant neuroblastoma, MIBG avid tumors, and cryopreserved AHSC. The nca-MIBG therapeutic dose was escalated in 3 mCi/kg increments from 12-21 mCi/kg using a 3+3 design. The administered dose was limited by gamma image-derived pretreatment organ dosimetry and normal tissue tolerance estimates of Emami (1991). AHSC were infused 14 days post therapy. Response and toxicity were evaluated day 60. Dose limiting toxicity (DLT) was failure to engraft or grade 3 or 4 non-hematologic toxicity except grade 3 pre-defined exclusions. Results: Fifteen eligible patients were treated with 8.8 to 18.6 mCi/kg, including 3 patients each entered and evaluable at levels 12, 15, 18 mCi/kg (444-666 GBq/kg) without required dose adjustment or DLT. Of six additional patients entered, one was inevaluable for DLT due to early disease progression, and the other five assigned to 21 mCi/kg required dose reductions of 13 to 45% to meet organ dose limits. Median whole body radiation dose received was 3.3 Gy (2.0-4.0); median liver dose, 11.6 Gy (9.1-25.8); lung 11.5 Gy (5.9-15.3); kidney 15.5 Gy (8.3-23.4); adrenal 3.3 (2.0-3.9); thyroid 35.7 (2.1-108). In 7 patients there were 12 target lesions (mass 1.8-175 g) with received doses of 26-378 Gy. There was no related grade 3 or 4 non-hematologic toxicity; all patients engrafted promptly. No patients at 15 or 18 mCi/kg had ANC<500. The overall response rate (complete + partial) was 27%; by dose received responses were 0/6 at 12 mCi/kg, 1/3 at 15 mCi/kg, and 3/6 at 18 mCi/kg. Conclusions: No-carrier added iobenguane-131 with AHSC support is feasible at 18 mCi/kg with an apparent dose/response. The promising responses support a pivotal phase IIb study of 18 mCi/kg.
The Flavonoid Wogonin Reduces CLL Cell Survival in Vitro and Leukemia Development in Eµ-TCL1 Mice By Targeting Aberrant TNF Receptor Signaling
Authors: Claudia Dürr, Bola Hanna, Fabienne McClanahan, Andrew James Clear, Thorsten Zenz, Stephan Stilgenbauer, John G. Gribben, Peter Lichter, Martina Seiffert
Journal: Blood (2014)
Lactobacillus-Deficient Cervicovaginal Bacterial Communities Are Associated with Increased HIV Acquisition in Young South African Women
Authors: Christina Gosmann, Melis N. Anahtar, Scott A. Handley, Mara Farcasanu, Galeb Abu-Ali, Brittany A. Bowman, Nikita Padavattan, Chandni Desai, Lindsay Droit, Amber Moodley, Mary Dong, Yuezhou Chen, Nasreen Ismail, Thumbi Ndung’u, Musie S. Ghebremichael, Duane R. Wesemann, Caroline Mitchell, Krista L. Dong, Curtis Huttenhower, Bruce D. Walker, Herbert W. Virgin, Douglas S. Kwon
Journal: Immunity (2017)
Tyrosine Kinase Proteins profiling of Nilotinib Resistant Chronic Myelogenous Leukemia Cells Unravels a Tyrosine Kinase-Mediated Bypass.
Authors: Jean-Max Pasquet, Romain Gioia, Claire Drullion, Valerie Lagarde, Cedric Leroy, Serge Roche, Bruno Cardinaud, Francois-Xavier Mahon
Journal: Blood (2009)
P2.08-003 Quality of Life and Patient Reported Outcome Measures for Lung Cancer Patients; Treatment Outcomes, and Patient Management
Authors: Winfield Boerckel, Carolyn Aldige, Dusty Donaldson, Hildy Grossman, Vicki Kennedy, Cindy Langhorne, Susan Mantel, Susan Rappaport, Maureen Rigney, Brian Tomlinson
Journal: Journal of Thoracic Oncology (2017)